

# Identification of *Brucella* (*Ochrobactrum*) *anthropi* by MALDI-TOF MS from blood: a case report

Maria Teresa Della Rocca<sup>1</sup>, Filomena Merola<sup>1</sup>, Adriana Durante<sup>1</sup>, Vittorio Panetta<sup>1</sup>, Stefano Labella<sup>1</sup>, Giuseppina Tucci<sup>1</sup>, Antonio Marino<sup>1</sup>, Giusy Natale<sup>1</sup>, Francesco Pardo<sup>2</sup>, Catia Sabbato<sup>2</sup>, Rita Greco<sup>1</sup>

<sup>1</sup>UOSD Microbiology, AORN Sant'Anna and San Sebastiano, Caserta; <sup>2</sup>UOC Emergency Medicine and Surgery, AORN Sant'Anna and San Sebastiano, Caserta, Italy

Correspondence: Rita Greco, UOSD Microbiology, AORN Sant'Anna and San Sebastiano, Caserta, Italy. E-mail: rita.greco@aorncaserta.it

Key words: alert organisms, nosocomial infection, MALDI-TOF, Brucella spp., Ochrobactrum anthropi.

Authors' contributions: all the authors made a substantive intellectual contribution. All the authors have read and approved the final version of the manuscript and agreed to be held accountable for all aspects of the work.

Conflict of interest: the authors declare no potential conflict of interest.

Funding: none.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: the patient gave her written consent to use her personal data for the publication of this case report and any accompanying images.

Availability of data and materials: all data generated or analyzed during this study are included in this published article.

Received: 27 September 2023. Accepted: 25 February 2024.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

<sup>©</sup>Copyright: the Author(s), 2024 Licensee PAGEPress, Italy Microbiologia Medica 2024; 39:11885 doi:10.4081/mm.2024.11885

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

# Summary

This case report describes the identification of *Ochrobactrum anthropi* (*O.a.*), from a positive blood culture using MALDI-TOF spectrometry system. According to the information available this is the first case in AORN Sant'Anna and San Sebastiano, Caserta, Campania, Italy. This microbe is moderately pathogenic and hazardous, with the potential to cause hospital-acquired infections. It is recommended that it be included in hospital "germ alerts".


### Introduction

Brucellaceae family consists of six genera in addition to Brucella (Ochrobactrum, Crabtreella, Daeguia, Mycoplana, Paenochrobactrum, and Pseudochrobactrum). Ochrobactrum is an alphaproteobacterium belonging to the Rhizobiales order divided in six species based on 16S rDNA sequencing (O. anthropi, O. intermedium, O. tritici, O. grignonense, O. gallinifaecis, and O. lupine) [9]. Ochrobactrum anthropi is a Gram-negative bacillus, non-fermenting bacillus, obligate aerobe bacillus, flagellate bacillus, oxidase-positive and indole-negative bacillus that thrives in the rhizosphere and does not multiply in host cells. This micro-organism exhibits low virulence and seldom causes human infections [9]. It is found in soil and water but can also be isolated from contaminated biological products, such as human wastes, fluids and medical devices [7]. Ochrobactrum anthropi has been described as an opportunistic pathogen that causes infections in severely ill or immunocompromised patients with indwelling catheterization, which can commonly lead to clinical manifestations such as catheter-related bloodstream infections [1,8]. In the last decade, O. anthropi has been associated to bacteremia, brain empyema, endophthalmitis, septic shock, septic arthritis, endocarditis [4]. In recent years, there have been reports O. anthropi clinical isolates resistant to multiple drugs, which have been linked to several hospital outbreaks [5]. Pathogen microbiological characterization is difficult due to its phenotypic similarities with other microorganisms, leading to potential mistakes in its diagnosis [6]. Based on molecular markers and genome comparisons, Brucella genus is closest to Ochrobactrum genus [3]. This case report describes the identification of O. anthropi using MALDI-TOF method and the importance of this emergent bacterium in hospital acquired infections. The patient gave her written consent for the publication of this case report.



# **Case Report**

An 84-year-old woman presented to our Emergency Department at AORN Sant'Anna and San Sebastiano with abdominal pain and generalized body aches. The woman had past history of cystitis, hyperthyroidism, hypertension and diabetes mellitus. Physical exam revealed globose abdomen, sore from palpation, hapless. Three days before hospital admission, she displayed rectorargy with blood in the stool and abdominal pain. Laboratory testing was significant for white blood cells (12.94x10<sup>3</sup>/uL), Lactate Dehydrogenase (LDH) (337 UI/L), elevated transaminase levels (52 UI/L). A chest X-ray was performed to check for the presence of a pneumonic focus or injuries; however, no sign of infection could be detected. CT and ultrasound abdomen showed no perceivable alterations. Aerobic and



The organism was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS, Biomèrieux, Marcy l'Étoile, France) as *Ochrobactrum anthropi* with 99.9% accuracy as a "claimed" organism (Figure 2). The identification was repeated with MALDI-TOF MS and confirmed with Vitek2 (Biomèrieux, Marcy l'Étoile, France).

Table 1 summarizes the Minimum Inhibitory Concentrations (MIC) values and interpretations tested with Vitek2. The inter-




Figure 1. Gram and culture characteristics of O. anthropi.




Figure 2. O. anthropi spectrum.



#### Table 1. Antibiotic susceptibility pattern of O. anthropi.

Antibiotics	MIC	Interpretation
Amikacin	8	R
Amoxicillin/Clavulanic acid	16	R
Aztreonam	32	R
Cefotaxime	8	R
Ceftazidime	16	R
Ceftazidime/Avibactam	16	R
Ceftolozane/Tazobactam	32	R
Ciprofloxacin	0.25	S
Levofloxacin	0,0094	S
Colistin	2	IE
Ertapenem	0.5	S
Gentamicin	1	R
Imipenem	≤0.5	S
Meropenem	0.5	S
Piperacillin/Tazobactam	32	R
Tigecycline	0.5	S
Tobramycin	≤1	NA
Trimethopim/Sulfamethoxazole	<1	IE

MIC, Minimum Inhibitory Concentration; R, resistant; S, sensible; IE, insufficient evidence; NA, not applicable.

pretation was reported following the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint tables [2].

The patient received levofloxacin (500mg IV/24 h) for 16 days. A new blood culture sample collected at the follow-up visit showed no bacterial growth after 5 days of incubation. At last follow-up, the patient had no symptoms consistent with relapsed disease.

# Discussion

This case report highlights the need for laboratories to adopt modern approaches for the identification and management of potential hospital-acquired infection micro-organisms. In the last years, the *Ochrobactrum* species has been considered an emerging hospital-acquired pathogen, but it has not yet been included among the "common" germ alert and it is likely to be underdiagnosed. Rapid microbiology is considered to be essential for identifying and differentiating the *Brucella species*, particularly due to the phenotypic similarities that makes species characterization by routine biochemical analysis difficult. In the current era of antimicrobial resistance, it is important to consider personalized antibiotic therapies as a potential solution to the therapeutic challenge. *O. anthropi* susceptibility patterns were in accordance with other cases of human infection in contrast to some reported cases that report this bacterium as multidrug-resistant. Treatment options were carefully considered and a combination therapy of ciprofloxacin and amikacin and/or trimethoprim-sulfamethoxazole was chosen. This particular therapy may be considered as a viable option for managing *O. anthropi* infections. *Ochrobactrum* spp. are not currently recognized as serious pathogens, so the idea that they may be harmless should be reconsidered.

# Conclusions

Despite the fact that *O.a.* is generally considered to be of low virulence and low risk compared to other non-fermenting Gramnegative *bacteria*, it should not be ignored as a potential cause of hospital-acquired infections. Consequently, it should be included in hospital germ alert notification. In microbiological and epidemiological order, *O.a.* could be a future difficult to threat pathogen, particularly in immunocompromised patients who might report Multi Drug Resistance (MDR) bacterial co-infections.

#### References

- 1. Ashraf F. A case of *Ochrobactrum anthropi*-induced septic shock and infective endocarditis. R I Med J 2016;99:27-8.
- 2. EUCAST Clinical breakpoints (v 13.1). Available from: https://www.eucast.org/clinical\_breakpoints
- 3. Foster JT, Beckstrom-Sternberg SM, Pearson T, et al. Wholegenome-based phylogeny and divergence of the genus *Brucella*. J Bacteriol 2009;191:2864-70.
- Menezes FG, Abreu MG, Kawagoe JY, et al. Ochrobactrum anthropi bacteremia in a preterm infant with cystic fibrosis. Braz J Microbiol 2014;45:559-61.
- 5. Mrozek S, Dupuy M, Hoarau L, et al. Brain empyema due to *Ochrobactrum anthropi*. Med Mal Infect 2014;44:128-9.
- Romano S, Aujoulat F, Jumas-Bilak E, et al. Multilocus sequence typing supports the hypothesis that *Ochrobactrum anthropi* displays a human-associated subpopulation. BMC Microbiol 2009;9:267.
- 7. Saveli CC, Levi M, Koeppe J. *Ochrobactrum anthropi* septic arthritis: case report and implications in orthopedic infections. Infect Dis Rep 2010;2:e2.
- Siti Rohani AH, Tzar MN. *Ochrobactrum anthropi* catheterrelated bloodstream infection: the first case report in Malaysia. Med J Malaysia 2013;68:267-8.
- 9. Vila A, Pagella H, Vera Bello G, Vicente A. *Brucella suis* bacteremia misidentified as Ochrobactrum anthropi by the VITEK 2 system. J Infect Dev Ctries 2016;10:432-6.